Taysha Gene Therapies’ (TSHA) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report published on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $10.00 price objective on the stock.

A number of other research analysts have also commented on TSHA. Wells Fargo & Company upped their price target on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. The Goldman Sachs Group set a $11.00 price objective on Taysha Gene Therapies in a report on Thursday, December 4th. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Chardan Capital reiterated a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Finally, Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Taysha Gene Therapies presently has an average rating of “Moderate Buy” and a consensus target price of $10.91.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA opened at $4.53 on Tuesday. The company has a market cap of $1.24 billion, a P/E ratio of -13.73 and a beta of 1.02. The firm’s fifty day moving average price is $4.87 and its two-hundred day moving average price is $4.42. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $6.02. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48.

Insider Buying and Selling

In other news, CEO Sean P. Nolan sold 41,312 shares of the company’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $190,448.32. Following the completion of the sale, the chief executive officer directly owned 2,908,257 shares in the company, valued at approximately $13,407,064.77. This represents a 1.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Sukumar Nagendran sold 26,918 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $124,091.98. Following the sale, the insider directly owned 1,317,389 shares in the company, valued at approximately $6,073,163.29. This trade represents a 2.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 598,623 shares of company stock valued at $2,822,188 over the last 90 days. 3.78% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors and hedge funds have recently bought and sold shares of TSHA. B Group Inc. boosted its stake in shares of Taysha Gene Therapies by 43.4% in the 2nd quarter. B Group Inc. now owns 1,800,556 shares of the company’s stock valued at $4,159,000 after purchasing an additional 545,000 shares in the last quarter. Rice Hall James & Associates LLC acquired a new position in Taysha Gene Therapies during the 3rd quarter worth approximately $1,890,000. GSA Capital Partners LLP lifted its stake in Taysha Gene Therapies by 969.0% in the 3rd quarter. GSA Capital Partners LLP now owns 477,749 shares of the company’s stock valued at $1,562,000 after purchasing an additional 433,059 shares during the last quarter. Affinity Asset Advisors LLC bought a new position in Taysha Gene Therapies in the 2nd quarter valued at approximately $462,000. Finally, Jefferies Financial Group Inc. boosted its position in Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after buying an additional 10,068,479 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.